This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Breast, Percutaneous, Biopsy, Cancer
Authors:
P. Merino Rasillo, E. Ortega García, P. Alonso Bartolomé, S. M. Sanchez Gomez, S. Sánchez Bernal, A. Vega Bolivar; Santander/ES
DOI:
10.1594/ecr2015/C-0644
Aims and objectives
Stereotactic vacuum-assisted biopsy (VAB) is widely used in place of surgical biopsy for the diagnosis of mammographically detected lesions of the breast.
Although stereotactic VAB has been shown to be highly accurate in diagnosing benign and malignant breast disease,
and is considered a safe procedure comparable to surgical biopsy for characterization of microcalcifications (1,2),
with low false-negative results (3,4).
However,
when a high-risk lesion is encountered VAB specimens,
the presence of an underlying malignancy within the lesion or in the nearby tissue can be underestimated.
As a consequence,
controversies about the best option for managing high-risk lesions exist and it´s a topic that continues to be discussed,
with the treatment of choice ranging from close imaging surveillance,
open surgical biopsy or chemoprophylactic therapy to prophylactic mastectomy in selected cases (5-8).
The purpose of this study was to determine the frequency of malignancy after surgical excision or a minimum of 2 years´ imaging follow-up of vacuum-assisted biopsied microcalcifications yielding a diagnosis of a high-risk lesion (atypical ductal hyperplasia [ADH],
flat epithelial atypia [FEA],
lobular neoplasia [LN],
papillomas,
radial scar and mucocele-like lesions).